In pan-cancer patients, the proportion of heterozygous CNV for KCC2 and NKCC1 is extraordinarily high, and KCC2 is mainly a form of heterozygous amplification, while NKCC1 is mainly a form of heterozygous deletion. Here, SLC12A2 is linked to cancer.